{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T19:38:24Z","timestamp":1778787504599,"version":"3.51.4"},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T00:00:00Z","timestamp":1740268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Study Objective<\/jats:title>\n                    <jats:p>The primary objective of this study was to determine if there was a significant change in potassium levels with sodium\u2010glucose co\u2010transporter\u20102 (SGLT2) inhibitor therapy in people with type 2 diabetes (T2D). A co\u2010primary objective was to evaluate which factors may predispose a patient to changes in potassium levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Multicenter retrospective cohort chart review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Source<\/jats:title>\n                    <jats:p>Study patients were identified through an electronic medical record\u2010generated report if they had T2D and were prescribed an SGLT2 inhibitor from January 2013 to September 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>Patients were included if they had T2D, were receiving care at Advocate Medical Group, and were confirmed to have taken one of the four SGLT2 inhibitors available at the time of study approval, canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin, for at least 7\u2009days. Patients were excluded if they did not have a basic metabolic panel or comprehensive metabolic panel recorded 1\u2009year prior to or 6\u2009months after SGLT2 inhibitor therapy initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Data extraction from the electronic medical record identified 6425 patients receiving an SGLT2 inhibitor, of which 1926 met inclusion criteria. The SGLT2 inhibitor most prescribed was canagliflozin (43.7%), followed by empagliflozin (36.9%) and dapagliflozin (19.4%). Concomitant baseline medications were thiazide diuretics (27.5%); angiotensin\u2010converting enzyme inhibitors, angiotensin II receptor blockers, or angiotensin receptor\u2010neprilysin inhibitors (72.1%); and\/or mineralocorticoid receptor antagonists (27.2%). A statistically significant change in potassium levels was found with dapagliflozin (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.018); albeit not clinically significant. No other statistically significant changes or patterns were identified. The overall mean change in serum potassium from baseline was 0.021\u2009mmol\/L within 3\u2009months; 0.007\u2009mmol\/L from 3 to 5.9\u2009months; \u22120.017\u2009mmol\/L within 6\u201312\u2009months; and 0.004\u2009mmol\/L after more than 12\u2009months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>No clinically significant increase or decrease in potassium levels was observed upon initiation of SGLT2 inhibitor therapy in patients with T2D. This was consistent across background medication use and patient\u2010specific factors. Baseline potassium should not be a factor in initiating SGLT2 inhibitor therapy, if clinically indicated, in patients with T2D.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/phar.70006","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T08:53:38Z","timestamp":1741683218000},"page":"194-202","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Changes in serum potassium in people with type 2 diabetes taking sodium\u2010glucose co\u2010transporter\u20102 inhibitors"],"prefix":"10.1002","volume":"45","author":[{"given":"Kellye","family":"Eagan","sequence":"first","affiliation":[{"name":"Riverside Medical Center  Kankakee Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9797-6557","authenticated-orcid":false,"given":"Charlotte","family":"Bolch","sequence":"additional","affiliation":[{"name":"Midwestern University Office of Research and Sponsored Programs  Glendale Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6138-1113","authenticated-orcid":false,"given":"Elizabeth","family":"Van Dril","sequence":"additional","affiliation":[{"name":"University of Illinois Chicago Herbert M. And Carol H. Retzky College of Pharmacy  Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6501-1590","authenticated-orcid":false,"given":"Christie","family":"Schumacher","sequence":"additional","affiliation":[{"name":"Midwestern University College of Pharmacy, Downers Grove Campus  Downers Grove Illinois USA"},{"name":"Advocate Health  Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,2,23]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-Sint"},{"issue":"18","key":"e_1_2_9_3_1","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich PA","year":"2022","journal-title":"Circulation"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-0614"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.919907"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00281818"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110239"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa133"},{"key":"e_1_2_9_14_1","unstructured":"INVOKANA\u00ae (canagliflozin) tablets for oral use [package insert]. Janssen Pharmaceuticals2023."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa243"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2034"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.057736"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab497"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2902"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000300"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08580813"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.70006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:13:35Z","timestamp":1761070415000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.70006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,23]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/phar.70006"],"URL":"https:\/\/doi.org\/10.1002\/phar.70006","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,23]]},"assertion":[{"value":"2024-11-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}